Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment

Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment

Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer

Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer

The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors

The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors

Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules

Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules

Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas

Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade

Studying the immune status of the tumor microenvironment with automated hyperplex immunofluorescence

Studying the immune status of the tumor microenvironment with automated hyperplex immunofluorescence

Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa

Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential

Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients

Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients